Illumina Obtains CDx Pan-Cancer Indication for TruSight Test

Illumina Obtains CDx Pan-Cancer Indication for TruSight Test

Source: 
Medical Devices and Diagnostics Industry
snippet: 

Illumina has won a companion diagnostic indication for its TruSight Oncology Comprehensive test to be used with Bayer’s Vitrakvi.

This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.